ZELTIQ Aesthetics Stock Rating Lowered by Goldman Sachs Group Inc. (ZLTQ)
ZELTIQ Aesthetics (NASDAQ:ZLTQ) was downgraded by Goldman Sachs Group Inc. from a “buy” rating to a “neutral” rating in a research note issued on Tuesday, TheFlyOnTheWall.com reports. They currently have a $21.00 price target on the stock, up from their previous price target of $19.00. Goldman Sachs Group Inc.’s target price suggests a potential upside of 2.79% from the company’s current price.
ZLTQ has been the subject of a number of other recent research reports. Analysts at Zacks downgraded shares of ZELTIQ Aesthetics from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, December 31st. They now have a $19.80 price target on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of ZELTIQ Aesthetics from $16.00 to $22.00 in a research note to investors on Friday, December 20th. They now have a “buy” rating on the stock. Finally, analysts at Cantor Fitzgerald initiated coverage on shares of ZELTIQ Aesthetics in a research note to investors on Thursday, November 21st. They set a “buy” rating and a $20.00 price target on the stock. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $17.96.
ZELTIQ Aesthetics (NASDAQ:ZLTQ) traded up 4.82% on Tuesday, hitting $20.43. 614,850 shares of the company’s stock traded hands. ZELTIQ Aesthetics has a 52 week low of $3.20 and a 52 week high of $24.30. The stock has a 50-day moving average of $18.50 and a 200-day moving average of $11.48. The company’s market cap is $744.1 million.
ZELTIQ Aesthetics (NASDAQ:ZLTQ) last announced its earnings results on Wednesday, October 30th. The company reported ($0.08) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.19) by $0.11. The company had revenue of $29.50 million for the quarter, compared to the consensus estimate of $21.30 million. On average, analysts predict that ZELTIQ Aesthetics will post $-0.52 earnings per share for the current fiscal year.
Zeltiq Aesthetics, Inc operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.